RS Research presents first-in-human phase 1 results of RS-0139 at ESMO Congress 2026
RS Research, a clinical-stage biotechnology company developing smart nanomedicines for targeted oncology therapies, presented detailed results from the completed Phase 1a/1b clinical trial of its lead investigational candidate, RS-0139, at ESMO Congress 2026, held in Madrid, Spain, on 23-27 October.
